Immunological profiling has revealed biological signatures of multiple sclerosis (MS) that could help with early, accurate diagnosis of the disease and with identifying disease subtypes that could inform treatment decisions. The findings are important steps along the path towards precision medicine for people with MS.
This is a preview of subscription content, log in via an institution to check access.
References
Zamecnik, C. R. et al. An autoantibody signature predictive for multiple sclerosis. Nat. Med. 30, 1300–1308 (2024).
Gross, C. C. et al. Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories. Sci. Transl. Med. 16, eade8560 (2024).
Kavaliunas, A. et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult. Scler. 23, 1233–1240 (2017).
University of California San Francisco MS-EPIC Team et al. Long-term evolution of multiple sclerosis disability in the treatment era. Ann. Neurol. 80, 499–510 (2016).
De Stefano, N. et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 74, 1868–1876 (2010).
Suthiphosuwan, S. et al. Paramagnetic rim sign in radiologically isolated syndrome. JAMA Neurol. 77, 653–655 (2020).
Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science 375, 296–301 (2022).
Cortese, M. et al. Serologic response to the Epstein-Barr virus peptidome and the risk for multiple sclerosis. JAMA Neurol. 81, 515–524 (2024).
Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58–64 (2020).
Bar-Or, A. et al. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials. EBioMedicine 93, 104662 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Oh, J., Bar-Or, A. Precision neuroimmunology in multiple sclerosis — the horizon is near. Nat Rev Neurol (2024). https://doi.org/10.1038/s41582-024-00992-6
Published:
DOI: https://doi.org/10.1038/s41582-024-00992-6
- Springer Nature Limited